PsychCME and CME Outfitters Announce Live CE Activity: 'Dosing and Receptors: Lessons Learned from CATIE' Premieres Wednesday, January 25, 2006
PsychCME and CME Outfitters are pleased to announce an upcoming live and interactive psychCME TV activity titled "Dosing and Receptors: Lessons Learned from CATIE." Offered as a live satellite broadcast, webcast, and telephone audioconference premiering Wednesday, January 25, 2006, from 12:00 p. m.–1:00 p. m. ET, the activity will focus on providing evidence-based educational information and clinical context regarding the efficacy of medications used to treat schizophrenia in the CATIE trial.
Rockville, MD (PRWEB) January 5, 2006
psychCME and CME Outfitters are pleased to announce an upcoming live and interactive psychCME TV activity titled "Dosing and Receptors: Lessons Learned from CATIE."
Offered as a live satellite broadcast, webcast, and telephone audioconference premiering Wednesday, January 25, 2006, from 12:00 p. m.–1:00 p. m. ET, the activity will focus on providing evidence-based educational information and clinical context regarding the efficacy of medications used to treat schizophrenia in the CATIE trial. The recorded satellite broadcast will re-air from 3:00 p. m.–4:00 p. m. ET. This CE activity will be available as an archived webcast, podcast, and telephone audioconference shortly after the live broadcast, and available as a videotape and multimedia CD-ROM in February 2006.
Participation in this activity is free, as is obtaining a CE certificate; however, registration is required. Three forms of registration are accepted:
Online: Visit the activity details page at http://www. cmeoutfitters. com/cmea. asp? ID=166 (http://www. cmeoutfitters. com/cmea. asp? ID=166)
Phone: Call 877.CME. PROS (877.263.7767)
Fax: Visit the activity details page at http://www. cmeoutfitters. com/cmea. asp? ID=166 (http://www. cmeoutfitters. com/cmea. asp? ID=166), print and complete the activity details form, and fax to 240.243.1033
Statement of Need:
In the past 10 years, five new atypical antipsychotic medications have been FDA-approved as a treatment for schizophrenia. They are collectively placed in the class of atypical, or second-generation, antipsychotics because they all share some advantages over older, first-generation antipsychotics. The distinguishing feature of second-generation antipsychotics is their lower propensity for causing extrapyramidal side effects. They also appear to have a broader spectrum of efficacy in reducing both positive symptoms (hallucinations and delusions) and negative symptoms (amotivation, emotional and social withdrawal), cognitive impairment, mood problems, and perhaps even persistent aggressive behavior. This broader efficacy may be due to differences in the agents’ receptor activity profile. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial is the most comprehensive independent trial comparing existing treatments for schizophrenia conducted thus far; however, information available from CATIE on dosing and two newer atypical antipsychotics, ziprasidone and aripiprazole, is limited. In this evidence-based psychCME TV activity, CATIE researchers will discuss these limitations in the context of receptor pharmacology of the atypical antipsychotics and what it means for the clinicians who are responsible for making informed, real-world decisions on dosing in patients with schizophrenia.
PsychCME Moderator:
Prakash S. Masand, MD
Consulting Professor of Psychiatry
Duke University Medical Center
Durham, NC
Faculty:
Jeffrey A. Lieberman, MD
Chairman, Department of Psychiatry
College of Physicians and Surgeons, Columbia University
Director, New York State Psychiatric Institute
Director, Lieber Center for Schizophrenia Research
Psychiatrist-in-Chief at New York Presbyterian Hospital & Columbia University Medical Center
New York, NY
John W. Newcomer, MD
Professor of Psychiatry, Psychology, and Medicine
Washington University School of Medicine
St. Louis, MO
Learning Objectives:
At the end of this CE activity, participants should be able to:
Compare and contrast receptor pharmacology of the atypical antipsychotics. Assess the relationship of receptor pharmacology to dosing, efficacy, and side effects. Apply a contextual framework to the existing CATIE data. Recognize the importance of providing individualized treatment strategies for patients with schizophrenia.
Target Audience:
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals with an interest in mental health.
Commercial Support:
CME Outfitters, LLC, gratefully acknowledges an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc., in support of this CE activity.
Credit Information:
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CME Outfitters, LLC, designates this educational activity for a maximum of 1.0 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.
CNE Credit (Nurses):
This Educational Activity is presented by CME Outfitters, LLC, which has been approved as a provider of continuing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. It has been assigned code 5UYSJZ-PRV-0485. 1.2 contact hours (Pharmacology)
CEP Credit (Psychologists):
CME Outfitters, LLC, is approved by the American Psychological Association to offer continuing education for psychologists. CME Outfitters, LLC, maintains responsibility for the program. 1.0 CE credits
NASW Credit (Social Workers):
This program was approved by the National Association of Social Workers (provider #886407722) for 1 continuing education contact hour.
CCMC Credit (Certified Case Managers):
This program has been approved for 1 hour by the Commission for Case Manager Certification (CCMC).
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Program Number: 376-999-06-005-L01 (live presentation) 376-999-06-005-H01 (recorded programs)
To receive credit, participants must review all activity materials in their entirety, score 70% or above on a post-test, and fully complete and return both the credit request form and activity evaluation. A certificate or statement of credit will be mailed within 4-6 weeks to all who successfully complete these requirements.
About CME Outfitters:
CME Outfitters is a full service healthcare communications agency providing continuing education content development, production, marketing, accreditation, and project management services to the healthcare industry. Among its many collaborative ventures, CME Outfitters enjoys an exclusive role in producing, certifying, and supporting the popular psychCME series of educational activities. For more information on CME Outfitters, including a complete calendar of its free award-winning educational activities, please visit http://www. cmeoutfitters. com (http://www. cmeoutfitters. com), or call 877.CME. PROS (877.263.7767).
To view all of CME Outfitters' recent press releases, visit http://www. cmeoutfitters. com (http://www. cmeoutfitters. com) and click on "CME Outfitters in the News" or visit http://www. prweb. com (http://www. prweb. com) and search for "CME Outfitters."
PsychCME EXTRA, a weekly e-newsletter published by CME Outfitters, is a convenient way to stay informed of all psychCME news and information. To subscribe, visit http://www. cmeoutfitters. com (http://www. cmeoutfitters. com) and click on "Register for Updates."
Contact: Jessica Primanzon
CME Outfitters, LLC
240.243.1308 direct
240.243.1033 fax
###
